Kite Pharma (KITE) Posts Q1 Loss of 20c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Kite Pharma (KITE) Posts Q1 Loss of 20c/Share
May 15, 2015 4:25 PM EDT
SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today reported financial results for the quarter ended March 31, 2015.
"We're very pleased with our accomplishments this year, which have significantly expanded our platform for discovering and advancing both chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. "We've entered into a broadly enabling CAR collaboration... More
May 15, 2015 4:25 PM EDT
SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today reported financial results for the quarter ended March 31, 2015.
"We're very pleased with our accomplishments this year, which have significantly expanded our platform for discovering and advancing both chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. "We've entered into a broadly enabling CAR collaboration... More
